Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Blueprint Medicines (NASDAQ:BPMC) in a research report sent to investors on Monday, Marketbeat.com reports. The firm issued a buy rating and a $135.00 target price on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Wedbush restated an “outperform” rating and issued a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Finally, Stephens reiterated an “overweight” rating and set a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $125.70.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC opened at $90.48 on Monday. The company has a market capitalization of $5.78 billion, a PE ratio of -83.78 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The stock has a fifty day moving average of $99.49 and a 200-day moving average of $93.96. Blueprint Medicines has a one year low of $80.68 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities analysts anticipate that Blueprint Medicines will post -1.28 EPS for the current fiscal year.

Insider Activity at Blueprint Medicines

In related news, insider Ariel Hurley sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the sale, the insider now directly owns 14,967 shares in the company, valued at approximately $1,496,700. The trade was a 13.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total value of $1,660,584.33. Following the transaction, the director now owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,334 shares of company stock valued at $3,103,512. Insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

Large investors have recently modified their holdings of the company. Swiss National Bank lifted its position in Blueprint Medicines by 1.6% during the 3rd quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock worth $10,748,000 after acquiring an additional 1,800 shares during the last quarter. Segall Bryant & Hamill LLC increased its stake in shares of Blueprint Medicines by 11.6% in the third quarter. Segall Bryant & Hamill LLC now owns 141,622 shares of the biotechnology company’s stock worth $13,100,000 after purchasing an additional 14,668 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth about $475,000. Advisors Asset Management Inc. boosted its stake in Blueprint Medicines by 17.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 756 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Blueprint Medicines in the 3rd quarter valued at approximately $6,465,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.